A recent survey showed healthcare as among the sectors US companies were most concerned about amid the ongoing China-US tensions over Taiwan. But how do biotech firms on the island itself view the current situation? We spoke to the president of one amid Taiwan’s imminent reopening.

A recent survey showed healthcare as the sector US public companies were most concerned about (after semiconductors) amid the ongoing China-US tensions over Taiwan. But how do biotech firms in Taiwan itself view the current situation? Scrip spoke to the president of one of the most innovative and active companies in the sector, amid the island’s imminent reopening to the world after over two long years under pandemic restrictions.

Where once there were promising prospects for cross-strait collaboration, biopharma firms in mainland China and Taiwan may now find themselves looking elsewhere for partners following a controversial visit to Taipei by US House Speaker Nancy Pelosi.

Approval total is one of FDA’s highest, but the large number of complete response letters obscures the staggering total of almost 80 new molecular entities and novel biologics that the agency acted on over the year.